Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of HYR-PB21 local infiltration for post-hemorrhoidectomy analgesia
CTR20234140Phase 3Completed
- Sponsor
- Hefei Cosource Pharmaceutical
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HYR-PB21 in postoperative pain and hemorrhoid (3 arms), sponsored by Hefei Cosource Pharmaceutical. Primary endpoint: AUC of resting pain intensity score from 0 to 72 hours. Started Dec 2023; status: completed.
02
Drugs
HYR-PB21
03
Conditions
postoperative painhemorrhoid
Beyond the preview
Go deeper on CTR20234140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234140.